Core Insights - Genvor, Inc. has published peer-reviewed research validating its AGM182 antifungal peptide technology, demonstrating a 76-98% reduction in aflatoxin contamination in transgenic corn [1][2][6] - The study highlights the economic impact of aflatoxin contamination, with annual U.S. losses from fungal diseases in corn estimated between $3 billion and $5 billion, and potential market impacts from aflatoxin contamination ranging from $52 million to $1.68 billion [2] Company Developments - The publication follows the issuance of U.S. Patent No. 12,458,684 for transgenic corn with AGM182, co-assigned with the USDA, providing intellectual property protection and scientific validation of the technology's commercial potential [3] - Genvor's CEO emphasized the significance of the peer-reviewed validation as a milestone for the AGM182 program, indicating the technology's potential to address major agricultural challenges [4] Research Collaboration - The research was conducted in collaboration with the USDA-ARS and Tuskegee University, building on over 7 years of cooperative research focused on developing corn varieties resistant to aflatoxin contamination [4][5] - The study confirms that computationally designed peptides can offer durable and scalable solutions for pre-harvest crop protection [4] Technology Efficacy - AGM182 has shown no adverse effects on plant growth or yield, and it possesses a proven mammalian safety profile with no observed toxicity [6] - The peptide demonstrates activity against key pathogens such as Aspergillus flavus and Fusarium species, which are significant contributors to yield loss and grain contamination [6]